# OnCo record juri-biosciences (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/juri-biosciences/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "juri-biosciences" ;
  schema:name "Juri Biosciences"@en ;
  schema:description "Juri Biosciences develops JUR-003, an antibody that directs the immune system's T cells to prostate cancer cells carrying a protein called KLK2. It is being tested for the first time in people with metastatic prostate cancer."@en ;
  schema:url <https://onco.cc/companies/juri-biosciences/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.tcglsoleil.com/news/juri-biosciences-a-tcg-labs-soleil-portfolio-company-and-epimab-biotherapeutics-enter-into-a-worldwide-licensing-agreement-for-klk2-directed-t-cell-engager-in-metastatic-prostate-cancer/>, <https://www.tcglsoleil.com/news/tcg-labs-soleil-highlights-portfolio-momentum-with-three-programs-entering-first-in-human-clinical-trials-across-oncology-and-cardiovascular-disease/>, <https://clinicaltrials.gov/study/NCT07824349> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/>, <https://onco.cc/cancers/prostate-mhspc/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:targets <https://onco.cc/targets/klk2/>, <https://onco.cc/targets/cd3/> .